Beneficial effects of botulinum toxin type A in trigeminal neuralgia

Zúñiga, Carlos; Díaz, Santiago; Piedimonte, Fabián; Micheli, Federico

doi:10.1590/s0004-282x2008000400012

Cited by 66 publications

(58 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 We subsequently reported 12 patients with ETN treated with BTX injections in an open-label trial, 10 of whom had a good response, suggesting that BTX could be an interesting tool in the management of such patients. 9 Since then, several case reports [12][13][14][15][16] and clinical trials with small number of patients [17][18][19][20] have shown similar results, with most patients responding to BTX (Table 2). Recently, Wu et al 21 reported a randomized, double-blind, placebo-controlled study of 42 subjects with ETN treated with BTX concluding that this therapy has beneficial effects among these patients.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Acute Treatment of Trigeminal Neuralgia With Onabotulinum Toxin A

Zúñiga¹,

Piedimonte²,

Díaz³

et al. 2013

Clinical Neuropharmacology

Self Cite

View full text Add to dashboard Cite

A double-blind, randomized, placebo-controlled study of patients with essential trigeminal neuralgia and treatment with a single injection of onabotulinum toxin A (BTX) was carried out. The efficacy, safety, and tolerability of either 1 mL 0.9% saline plus 50 U of BTX or only 1 mL of 0.9% saline injected subcutaneously in the affected area were evaluated. Cases with involvement of the third branch of the trigeminal nerve also received intramuscularly either 10 U of BTX or matching placebo in the masseter muscle, ipsilateral to the pain location. Pain was assessed with the visual analog scale (VAS). Twenty subjects were administered BTX, and 16 subjects received placebo. Two months after the intervention, a trend to statistical significance was observed for the VAS mean values in subjects treated with BTX and those who received placebo (VAS 4.9 vs 6.63, t test, P = 0.07). Three months after the injection, significant differences were observed in the average VAS score for subjects treated with BTX and those treated with placebo (VAS 4.75 vs 6.94, respectively; t test, P = 0.01). Onabotulinum toxin A was well tolerated and seems to be a safe and useful therapy for patients with essential trigeminal neuralgia.

show abstract

Section: Discussionmentioning

confidence: 91%

“…Unfortunately, some patients continue to have persistent or recurrent painful attacks even despite multiple operations. 8 Based on previous results, 9 we conducted a double-blind, randomized, controlled trial of onabotulinum toxin type A versus placebo in the management of pain due to ETN.…”

mentioning

confidence: 99%

Acute Treatment of Trigeminal Neuralgia With Onabotulinum Toxin A

Zúñiga¹,

Piedimonte²,

Díaz³

et al. 2013

Clinical Neuropharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Many studies have gradually confirmed the effectiveness of BTX-A for next ten years [5,[15][16][17][18][19][20]. But until 2012, it still has doubts about the effect of BTX-A in treatment of TN [21].…”

Section: Commentarymentioning

confidence: 99%

Two Doses of Botulinum Toxin Type A for the Treatment of Trigeminal Neuralgia: Observation of Therapeutic Effect from A Randomized, Placebo-Controlled Trial

Zhang¹,

Lian²

2017

Toxicol Open Access

View full text Add to dashboard Cite

“…The effect of the botulinum toxin is analgesic, but it never acts as a monotherapy without neurological medications. 20 …”

Section: Trigeminal Neuralgymentioning

confidence: 99%

Effective applications of botulinum toxin in dentistry and in head and neck surgery

Smucler¹,

Jenča²,

Jenčová³

2017

EDUJ

View full text Add to dashboard Cite

Cite this article:Šmucler R, Jenča A, Jenčova J. Effective applications of botulinum toxin in dentistry and in head and neck surgery. Stoma Edu J. 2017;4(3):200-207.Background: Botulinum toxin A and B is approved for the treatment of many diseases, and we can read many papers experimenting with other possibilities. The use of botulinum toxin is a relatively new option with little or no pre-gradual training in dentistry. Objective: This article aims to summarise current knowledge in this emerging field. Data Sources: A search of MEDLINE, EMBASE, bibliographies of published systematic reviews was performed, as well as of the Cochrane trial registries between 1966 and June 10, 2016. Study Selection: Randomized controlled trials comparing botulinum toxin A with placebo or other interventions were preferred, but for many emerging indication we used non-randomized studies as well to inspire further studies. Data Extraction: Data were abstracted and quality assessed by 1 reviewer. Data Synthesis: We have little-randomised data to quantify the effect of botulinum toxin in a majority of indications in dentistry precisely. Conclusion:The rapid development of the botulinum toxin application brings new possibilities for treatment by dentists alone or in cooperation with other specialists. Besides the above-verified evidencebased indications, there are new and new case studies quickly appearing that need to be monitored and possibly applied. But we have very few randomised studies to make final guidelines in many indications, so further scientific works are really needed. Botulinum toxin should be part of undergraduate and postgraduate teaching.

show abstract

Beneficial effects of botulinum toxin type A in trigeminal neuralgia

Cited by 66 publications

References 20 publications

Acute Treatment of Trigeminal Neuralgia With Onabotulinum Toxin A

Acute Treatment of Trigeminal Neuralgia With Onabotulinum Toxin A

Two Doses of Botulinum Toxin Type A for the Treatment of Trigeminal Neuralgia: Observation of Therapeutic Effect from A Randomized, Placebo-Controlled Trial

Effective applications of botulinum toxin in dentistry and in head and neck surgery

Contact Info

Product

Resources

About